{
    "clinical_study": {
        "@rank": "63778", 
        "arm_group": [
            {
                "arm_group_label": "FIASP", 
                "arm_group_type": "Experimental", 
                "description": "Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal."
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect\n      of the investigated drug on the body) properties of FIAsp (faster-acting insulin aspart) in\n      subjects with type 1 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index 18.5-28.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent\n             per day)\n\n          -  Not able or willing to refrain from smoking and use of nicotine substitute products\n             during the inpatient period inpatient period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924637", 
            "org_study_id": "NN1218-3889", 
            "secondary_id": [
                "2011-000941-19", 
                "U1111-1119-5708"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "FIASP", 
                "description": "A single dose will be administered subcutaneously (under the skin) in the abdomen.\nEach subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.", 
                "intervention_name": "insulin aspart (FIAsp)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "description": "A single dose will be administered subcutaneously (under the skin)) in the abdomen.\nEach subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 10, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8010"
                }
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean change in plasma glucose concentration", 
            "safety_issue": "No", 
            "time_frame": "From 0-2 hours after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin aspart concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 1 hour"
            }, 
            {
                "measure": "Area under the serum insulin aspart concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 12 hours"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}